Do analysts rate GMTX or KURA?

Kura Oncology has a consensus target price of $25.62, indicating a potential upside of 135.87%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Kura Oncology is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Kura Oncology 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69

Does the media prefer KURA or CLDX?

In the previous week, Kura Oncology had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 23 mentions for Kura Oncology and 19 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.79 beat Kura Oncology's score of 0.69 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Celldex Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor KURA or NAMS?

In the previous week, Kura Oncology had 13 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 23 mentions for Kura Oncology and 10 mentions for NewAmsterdam Pharma. Kura Oncology's average media sentiment score of 0.69 beat NewAmsterdam Pharma's score of -0.23 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive NewAmsterdam Pharma 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MBX or KURA?

In the previous week, Kura Oncology had 18 more articles in the media than MBX Biosciences. MarketBeat recorded 23 mentions for Kura Oncology and 5 mentions for MBX Biosciences. Kura Oncology's average media sentiment score of 0.69 beat MBX Biosciences' score of 0.52 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer KURA or IDYA?

In the previous week, Kura Oncology had 20 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 23 mentions for Kura Oncology and 3 mentions for IDEAYA Biosciences. Kura Oncology's average media sentiment score of 0.69 beat IDEAYA Biosciences' score of 0.38 indicating that Kura Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kura Oncology 6 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive IDEAYA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kura Oncology (KURA) Competitors

$10.86 +0.77 (+7.63%)

Closing price 04:00 PM Eastern

Extended Trading

$10.91 +0.05 (+0.45%)

As of 07:34 PM Eastern

Compare

KURA vs. GMTX, CLDX, NAMS, MBX, and IDYA

Should you buy Kura Oncology stock or one of its competitors? Kura Oncology's main competitors and comparable companies include Gemini Therapeutics (GMTX), Celldex Therapeutics (CLDX), NewAmsterdam Pharma (NAMS), MBX Biosciences (MBX), and IDEAYA Biosciences (IDYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kura Oncology compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends.

Gemini Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Gemini Therapeutics' return on equity of -38.78% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Kura Oncology	-384.30%	-207.18%	-45.17%

Kura Oncology has a consensus target price of $25.62, indicating a potential upside of 135.87%. Given Kura Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Kura Oncology is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 7.6% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Kura Oncology had 23 more articles in the media than Gemini Therapeutics. MarketBeat recorded 23 mentions for Kura Oncology and 0 mentions for Gemini Therapeutics. Kura Oncology's average media sentiment score of 0.69 beat Gemini Therapeutics' score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Gemini Therapeutics	Neutral
Kura Oncology	Positive

Gemini Therapeutics has higher earnings, but lower revenue than Kura Oncology. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Kura Oncology	$77.23M	12.48	-$278.67M	-$3.37	N/A

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market.

Summary

Kura Oncology beats Gemini Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Kura Oncology compare to Celldex Therapeutics?

Kura Oncology (NASDAQ:KURA) and Celldex Therapeutics (NASDAQ:CLDX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Celldex Therapeutics has lower revenue, but higher earnings than Kura Oncology. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$77.23M	12.48	-$278.67M	-$3.37	N/A
Celldex Therapeutics	$1.54M	2,139.18	-$258.76M	-$4.35	N/A

Kura Oncology has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Celldex Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. Celldex Therapeutics' return on equity of -52.35% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
Celldex Therapeutics	N/A	-52.35%	-47.61%

In the previous week, Kura Oncology had 4 more articles in the media than Celldex Therapeutics. MarketBeat recorded 23 mentions for Kura Oncology and 19 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.79 beat Kura Oncology's score of 0.69 indicating that Celldex Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	6 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Celldex Therapeutics	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Kura Oncology currently has a consensus target price of $25.62, indicating a potential upside of 135.87%. Celldex Therapeutics has a consensus target price of $55.46, indicating a potential upside of 32.21%. Given Kura Oncology's higher possible upside, research analysts clearly believe Kura Oncology is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Celldex Therapeutics beats Kura Oncology on 9 of the 15 factors compared between the two stocks.

How does Kura Oncology compare to NewAmsterdam Pharma?

Kura Oncology (NASDAQ:KURA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Kura Oncology has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market.

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NewAmsterdam Pharma has lower revenue, but higher earnings than Kura Oncology. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$77.23M	12.48	-$278.67M	-$3.37	N/A
NewAmsterdam Pharma	$22.50M	143.34	-$203.82M	-$2.16	N/A

Kura Oncology currently has a consensus price target of $25.62, suggesting a potential upside of 135.87%. NewAmsterdam Pharma has a consensus price target of $49.33, suggesting a potential upside of 82.85%. Given Kura Oncology's higher probable upside, equities analysts plainly believe Kura Oncology is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Kura Oncology has a net margin of -384.30% compared to NewAmsterdam Pharma's net margin of -3,644.21%. NewAmsterdam Pharma's return on equity of -34.81% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
NewAmsterdam Pharma	-3,644.21%	-34.81%	-31.50%

In the previous week, Kura Oncology had 13 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 23 mentions for Kura Oncology and 10 mentions for NewAmsterdam Pharma. Kura Oncology's average media sentiment score of 0.69 beat NewAmsterdam Pharma's score of -0.23 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	6 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
NewAmsterdam Pharma	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NewAmsterdam Pharma beats Kura Oncology on 9 of the 16 factors compared between the two stocks.

How does Kura Oncology compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Kura Oncology (NASDAQ:KURA) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

MBX Biosciences has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

MBX Biosciences currently has a consensus target price of $75.63, suggesting a potential upside of 10.29%. Kura Oncology has a consensus target price of $25.62, suggesting a potential upside of 135.87%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

MBX Biosciences has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. MBX Biosciences' return on equity of -26.02% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Kura Oncology	-384.30%	-207.18%	-45.17%

In the previous week, Kura Oncology had 18 more articles in the media than MBX Biosciences. MarketBeat recorded 23 mentions for Kura Oncology and 5 mentions for MBX Biosciences. Kura Oncology's average media sentiment score of 0.69 beat MBX Biosciences' score of 0.52 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	6 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

MBX Biosciences has higher earnings, but lower revenue than Kura Oncology. MBX Biosciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Kura Oncology	$77.23M	12.48	-$278.67M	-$3.37	N/A

Summary

MBX Biosciences and Kura Oncology tied by winning 7 of the 14 factors compared between the two stocks.

How does Kura Oncology compare to IDEAYA Biosciences?

Kura Oncology (NASDAQ:KURA) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Kura Oncology has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market.

Kura Oncology currently has a consensus price target of $25.62, suggesting a potential upside of 135.87%. IDEAYA Biosciences has a consensus price target of $50.13, suggesting a potential upside of 38.09%. Given Kura Oncology's higher possible upside, equities analysts clearly believe Kura Oncology is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

IDEAYA Biosciences has higher revenue and earnings than Kura Oncology. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$77.23M	12.48	-$278.67M	-$3.37	N/A
IDEAYA Biosciences	$218.71M	14.58	-$113.70M	-$1.94	N/A

98.3% of IDEAYA Biosciences shares are held by institutional investors. 7.6% of Kura Oncology shares are held by insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Kura Oncology had 20 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 23 mentions for Kura Oncology and 3 mentions for IDEAYA Biosciences. Kura Oncology's average media sentiment score of 0.69 beat IDEAYA Biosciences' score of 0.38 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	6 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
IDEAYA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

IDEAYA Biosciences has a net margin of -75.93% compared to Kura Oncology's net margin of -384.30%. IDEAYA Biosciences' return on equity of -16.73% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	-384.30%	-207.18%	-45.17%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

Summary

IDEAYA Biosciences beats Kura Oncology on 10 of the 16 factors compared between the two stocks.

Get Kura Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KURA vs. The Competition

Export

Metric	Kura Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$895.73M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-3.22	10.67	269.06	25.28
Price / Sales	12.48	1,262.99	592.57	87.62
Price / Cash	N/A	102.88	70.48	50.90
Price / Book	19.75	16.78	12.91	6.24
Net Income	-$278.67M	-$13.32M	$3.45B	$347.60M
7 Day Performance	13.48%	1.74%	1.12%	1.07%
1 Month Performance	-3.38%	1.60%	1.79%	1.03%
1 Year Performance	64.55%	56.43%	67.69%	20.77%

Kura Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KURA Kura Oncology	2.948 of 5 stars	$10.86 +7.6%	$25.62 +135.9%	+55.5%	$895.73M	$77.23M	N/A	130	Trending News Earnings Report Analyst Forecast Analyst Revision
GMTX Gemini Therapeutics	N/A	$77.44 flat	N/A	+36.5%	$3.36B	N/A	N/A	30
CLDX Celldex Therapeutics	2.903 of 5 stars	$42.97 +3.0%	$55.46 +29.1%	+70.5%	$3.27B	$1.54M	N/A	150	Analyst Revision
NAMS NewAmsterdam Pharma	2.56 of 5 stars	$27.98 +0.1%	$49.33 +76.3%	+3.5%	$3.27B	$22.50M	N/A	4
MBX MBX Biosciences	2.1984 of 5 stars	$66.15 -2.5%	$75.63 +14.3%	N/A	$3.27B	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KURA) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kura Oncology (KURA) Competitors

KURA vs. GMTX, CLDX, NAMS, MBX, and IDYA

How does Kura Oncology compare to Gemini Therapeutics?

Summary

How does Kura Oncology compare to Celldex Therapeutics?

Summary

How does Kura Oncology compare to NewAmsterdam Pharma?

Summary

How does Kura Oncology compare to MBX Biosciences?

Summary

How does Kura Oncology compare to IDEAYA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kura Oncology (KURA) Competitors

KURA vs. GMTX, CLDX, NAMS, MBX, and IDYA

How does Kura Oncology compare to Gemini Therapeutics?

Is GMTX or KURA more profitable?

Do analysts rate GMTX or KURA?

Do institutionals & insiders believe in GMTX or KURA?

Does the media prefer GMTX or KURA?

Which has stronger earnings & valuation, GMTX or KURA?

Which has more volatility and risk, GMTX or KURA?

Summary

How does Kura Oncology compare to Celldex Therapeutics?

Which has preferable earnings and valuation, KURA or CLDX?

Which has more risk and volatility, KURA or CLDX?

Is KURA or CLDX more profitable?

Does the media prefer KURA or CLDX?

Do analysts rate KURA or CLDX?

Summary

How does Kura Oncology compare to NewAmsterdam Pharma?

Which has more volatility & risk, KURA or NAMS?

Do insiders and institutionals hold more shares of KURA or NAMS?

Which has better valuation and earnings, KURA or NAMS?

Do analysts recommend KURA or NAMS?

Is KURA or NAMS more profitable?

Does the media favor KURA or NAMS?

Summary

How does Kura Oncology compare to MBX Biosciences?

Which has more volatility & risk, MBX or KURA?

Do analysts prefer MBX or KURA?

Is MBX or KURA more profitable?

Does the media refer more to MBX or KURA?

Which has preferable valuation and earnings, MBX or KURA?

Summary

How does Kura Oncology compare to IDEAYA Biosciences?

Which has more risk and volatility, KURA or IDYA?

Do analysts rate KURA or IDYA?

Which has preferable valuation and earnings, KURA or IDYA?

Do institutionals and insiders have more ownership in KURA or IDYA?

Does the media prefer KURA or IDYA?

Is KURA or IDYA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA vs. The Competition

Kura Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools